- Home
- BAND vs CRVS Comparison
BAND vs CRVS Comparison
Compare BAND & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAND
- CRVS
- Stock Information
- Founded
- BAND 2000
- CRVS 2014
- Country
- BAND United States
- CRVS United States
- Employees
- BAND N/A
- CRVS N/A
- Industry
- BAND Computer Software: Prepackaged Software
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- BAND Technology
- CRVS Health Care
- Exchange
- BAND Nasdaq
- CRVS Nasdaq
- Market Cap
- BAND 358.3M
- CRVS 305.4M
- IPO Year
- BAND 2017
- CRVS 2016
- Fundamental
- Price
- BAND $13.55
- CRVS $4.24
- Analyst Decision
- BAND Buy
- CRVS Strong Buy
- Analyst Count
- BAND 6
- CRVS 4
- Target Price
- BAND $20.80
- CRVS $15.00
- AVG Volume (30 Days)
- BAND 345.4K
- CRVS 439.9K
- Earning Date
- BAND 07-29-2025
- CRVS 08-12-2025
- Dividend Yield
- BAND N/A
- CRVS N/A
- EPS Growth
- BAND N/A
- CRVS N/A
- EPS
- BAND N/A
- CRVS N/A
- Revenue
- BAND $758,106,000.00
- CRVS N/A
- Revenue This Year
- BAND $2.36
- CRVS N/A
- Revenue Next Year
- BAND $13.56
- CRVS N/A
- P/E Ratio
- BAND N/A
- CRVS N/A
- Revenue Growth
- BAND 14.51
- CRVS N/A
- 52 Week Low
- BAND $11.33
- CRVS $2.54
- 52 Week High
- BAND $23.00
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- BAND 38.62
- CRVS 48.38
- Support Level
- BAND $12.92
- CRVS $3.96
- Resistance Level
- BAND $16.45
- CRVS $4.98
- Average True Range (ATR)
- BAND 0.76
- CRVS 0.22
- MACD
- BAND -0.30
- CRVS -0.05
- Stochastic Oscillator
- BAND 15.04
- CRVS 24.99
About BAND Bandwidth Inc.
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of our revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).